<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drug-induced lung disease in rheumatoid arthritis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drug-induced lung disease in rheumatoid arthritis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Drug-induced lung disease in rheumatoid arthritis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fiona R Lake, MD, FRACP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joyce S Lee, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul F Dellaripa, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Drug-induced pulmonary disease is an important consideration in the differential diagnosis of patients with rheumatoid arthritis (RA) who present with respiratory symptoms [<a href="#rid1">1</a>]. Knowledge of the types of lung toxicity that are associated with the individual agents used to treat RA, the patterns of lung disease that are associated with RA (unrelated to medication), and the spectrum of potential comorbid disease processes will help in the diagnosis and management of drug-induced lung disease. </p><p>A review of drug-induced lung disease in patients with RA will be presented here. Other aspects of pulmonary disease associated with rheumatoid arthritis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">"Overview of pleuropulmonary diseases associated with rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/4362.html" rel="external">"Interstitial lung disease in rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/7511.html" rel="external">"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>A number of drugs used to treat RA can induce alveolar inflammation, interstitial inflammation, and/or interstitial fibrosis (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pneumotox.com%2F&amp;token=xXI%2By9QNEPjV52%2B%2BDeHAede6O3UKh%2BRRgqigIy%2FxLGWFGLjmFLnJS66U7KXZE6%2By&amp;TOPIC_ID=4378" target="_blank">Pneumotox.com</a>), although the exact pathogenesis of the toxicity is unknown [<a href="#rid2">2,3</a>]. The risk and type of lung toxicity varies among the different agents. (See <a class="local">'Features of individual agents'</a> below.)</p><p>In addition to direct lung toxicity, virtually all of the disease modifying antirheumatic drugs (DMARDs) have immunosuppressive effects that increase the risk of bacterial and opportunistic lung infection [<a href="#rid4">4-6</a>]. As an example, in an observational study of 16,788 patients with RA, patients taking <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> had a higher risk of hospitalization due to pneumonia than patients not taking glucocorticoids (hazard ratio 1.7, 95% CI 1.5-2.0) [<a href="#rid7">7</a>]. The effect was dose dependent. Although <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and tumor necrosis factor (TNF) antagonists were not associated with an increased risk of pneumonia in this study, they have been associated with pneumonia in other studies [<a href="#rid8">8-16</a>]. (See  <a class="medical medical_review" href="/z/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>The net effect of the disease modifying antirheumatic drugs (DMARDs) on the incidence of drug-induced lung disease in patients with RA is uncertain. Medication side effects may become more common as the clinical use of DMARDs and biological agents such as tumor necrosis factor (TNF) blockers increases [<a href="#rid17">17-20</a>].</p><p>Conversely, DMARDs may have a beneficial impact on the natural history of a variety of forms of rheumatoid-associated lung disease, and use of these drugs may influence the frequency or presentation of these problems [<a href="#rid21">21</a>]. In one study of 59 patients with RA who were taking DMARDs but had no pulmonary symptoms, abnormal histology on transbronchial lung biopsy was found in 18 percent of patients on DMARDs, compared to 42 percent of those not taking one of these drugs [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H3400844"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical manifestations of drug-induced lung disease are variable and nonspecific. Symptoms, when present, can develop days to years into therapy and can progress rapidly or indolently. Drug-induced lung disease is one of the causes of rapid progression of interstitial lung disease (ILD) to respiratory failure. Symptoms include cough, dyspnea, low-grade fever, and occasionally a rash. Lung auscultation may reveal focal or bibasilar crackles, but is often normal.</p><p class="headingAnchor" id="H105098521"><span class="h1">EVALUATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>Drug-induced lung disease is often a diagnosis of exclusion, so the diagnostic approach involves a combination of tests designed to exclude other processes (eg, heart failure, infection, RA-associated interstitial lung disease) and to identify features that are suggestive of a drug-induced process (eg, timing of symptoms relative to drug initiation, eosinophilia in blood or bronchoalveolar lavage fluid). Empiric drug discontinuation is an important diagnostic step. Underlying lung disease due to RA or cigarette smoking may complicate determination of whether current symptoms are caused by a new process or progression/exacerbation of a preexisting process. General approaches to interstitial lung disease and to lung disease in patients with RA are described separately. (See  <a class="medical medical_review" href="/z/d/html/4362.html" rel="external">"Interstitial lung disease in rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">"Approach to the adult with interstitial lung disease: Clinical evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing"</a> and  <a class="medical medical_review" href="/z/d/html/16921.html" rel="external">"Interpretation of lung biopsy results in interstitial lung disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong> – Laboratory testing is used to determine whether other disease processes are contributing to the patient's respiratory compromise. Complete cell counts and differential are obtained to look for anemia (suggestive of alveolar hemorrhage), neutrophilia (suggestive of infection), or eosinophilia (suggestive of drug hypersensitivity or fungal infection). B-type natriuretic peptide (BNP) can help exclude heart failure as an etiology. Blood cultures, sputum cultures, C-reactive protein (CRP), and serologic studies can also help to identify infectious causes. (See  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing", section on 'Laboratory tests'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – A chest radiograph is obtained to assess the pattern and extent of disease but high resolution computed tomography of the chest is usually needed for full characterization. Various radiographic patterns of drug-induced injury are described, including patchy or diffuse, unilateral or bilateral reticular markings, ground glass opacities, or consolidation, and pulmonary nodules with or without cavitation. Newly appearing or enlarging pulmonary nodules have been associated with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>. Pleural effusions have been associated with methotrexate [<a href="#rid3">3</a>]. (See <a class="local">'Methotrexate'</a> below and <a class="local">'Leflunomide'</a> below.)</p><p></p><p class="bulletIndent1">Hilar lymphadenopathy is an uncommon manifestation of drug induced disease, except in the case of methotrexate-associated lymphoproliferative disease or anti-tumor necrosis factor-alpha-induced lymphadenopathy. (See  <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">"Methotrexate-induced lung injury", section on 'Pulmonary lymphoproliferative disease'</a> and <a class="local">'Granulomatous lung disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary Physiology</strong> – Frequently, patients are too unwell for complete lung function testing, but if they can be obtained, they can aid in documenting changes in lung function. At a minimum, pulse oxygen saturation (SpO<sub>2</sub>) at rest and importantly on exertion, such as during a six-minute walk test (6MWT), is helpful in determining the severity of impairment. Hypoxemia at rest or with exertion is common. (See  <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p></p><p class="bulletIndent1">While uncommon, a diffusing capacity for carbon monoxide (DLCO) above the predicted range suggests pulmonary hemorrhage. (See  <a class="medical medical_review" href="/z/d/html/6972.html" rel="external">"Diffusing capacity for carbon monoxide", section on 'Increased DLCO'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchoscopy</strong> – After review of clinical findings, laboratory data, and chest imaging, bronchoscopy with bronchoalveolar lavage (BAL) may be needed to exclude processes such as infection, diffuse alveolar hemorrhage, or lymphangitic spread of tumor (eg, in the presence of fever, widespread or nodular opacities on chest imaging, or rapidly progressive respiratory impairment). </p><p></p><p class="bulletIndent1">There are no specific findings for drug-induced lung toxicity on bronchoscopy or BAL. BAL fluid cell counts are usually elevated, but the pattern of cellularity is nonspecific. Lymphocytosis, neutrophilia, or eosinophilia may be seen; among these, eosinophilia is more suggestive of a drug-induced process. Thus, the main role of bronchoscopy is to exclude alternative diagnoses. (See  <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">"Basic principles and technique of bronchoalveolar lavage"</a> and  <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to therapy</strong> – Empiric withdrawal of the implicated drug is a key diagnostic and therapeutic step. In general, noninfectious drug-related lung disease often regresses upon withdrawal of the offending medication. After exclusion of infection, a prompt response to systemic glucocorticoid therapy may be a distinguishing feature of drug-induced lung disease, which often responds better to glucocorticoid therapy than RA-related interstitial lung disease. (See  <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">"Overview of pleuropulmonary diseases associated with rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/4362.html" rel="external">"Interstitial lung disease in rheumatoid arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung biopsy – </strong>Lung biopsy is usually not required, and many patients may be too unwell to undergo this procedure. Often, the clinical picture, radiologic findings, and BAL results excluding infection are sufficiently convincing of the diagnosis to make a biopsy unnecessary, particularly in patients who respond quickly to drug discontinuation. In contrast, a lung biopsy is indicated when the patient has acute, progressive or severe disease and the cause of the pneumonitis is uncertain or when lymphoproliferative disease is suspected on the basis of nodular opacities, and when the biopsy findings will change therapy. </p><p></p><p class="bulletIndent1">Lung biopsy rarely establishes an antirheumatic agent as the definitive source of the lung injury, as there are no pathognomonic findings, and histologic criteria for drug-induced lung disease have not been established [<a href="#rid23">23</a>]. However, when available, lung histopathology can characterize the histopathologic pattern (eg, lymphocytic, granulomatous, eosinophilic, or organizing pneumonia or diffuse alveolar damage), which may help to guide therapy. (See  <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">"Role of lung biopsy in the diagnosis of interstitial lung disease"</a> and  <a class="medical medical_review" href="/z/d/html/16921.html" rel="external">"Interpretation of lung biopsy results in interstitial lung disease"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differentiation between a drug reaction, underlying rheumatoid-associated lung disease, infection, and heart failure may be difficult, since there is significant overlap in the clinical syndromes. In addition, many of the pulmonary reactions to drugs used for the treatment of rheumatoid arthritis are rare and are published as case reports  (<a class="graphic graphic_table graphicRef65141" href="/z/d/graphic/65141.html" rel="external">table 1</a>). An online repository of drug-induced lung disease is available to help identify potential culprit medications (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pneumotox.com%2F&amp;token=xXI%2By9QNEPjV52%2B%2BDeHAede6O3UKh%2BRRgqigIy%2FxLGWFGLjmFLnJS66U7KXZE6%2By&amp;TOPIC_ID=4378" target="_blank">Pneumotox.com</a>) [<a href="#rid2">2</a>]. When patients present with fever, rapidly progressive respiratory insufficiency, or widespread or nodular opacities on chest imaging, bacterial and opportunistic lung infections are high on the differential and should be pursued vigorously. (See <a class="local">'Evaluation and diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/1401.html" rel="external">"Approach to the immunocompromised patient with fever and pulmonary infiltrates"</a>.)</p><p class="headingAnchor" id="H360853949"><span class="h1">FEATURES OF INDIVIDUAL AGENTS</span></p><p class="headingAnchor" id="H5"><span class="h2">Methotrexate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> (MTX) is the most commonly used disease modifying antirheumatic drug (DMARD) in RA. Pulmonary complications of methotrexate are not associated with folate deficiency and may infrequently occur with the relatively low doses (&lt;20 mg per week) that are used in patients with RA [<a href="#rid24">24-26</a>]. The risk factors, clinical manifestations, diagnosis, and treatment of MTX-induced pneumonitis are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a> and  <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">"Methotrexate-induced lung injury"</a>.)</p><p>Acute or subacute interstitial pneumonitis typically presents with nonproductive cough, dyspnea, and sometimes fever or chest pain after weeks to months of oral therapy. Among patients with a subacute onset of MTX-induced lung disease, up to 50 percent demonstrate peripheral blood eosinophilia, which strongly supports the diagnosis, when present. Early drug discontinuation at the onset of respiratory symptoms may obviate the need for invasive testing.</p><p>Less commonly, interstitial fibrosis, accelerated rheumatoid lung nodulosis, asthma, and air trapping have been reported during MTX treatment. In many cases, it is not clear whether these less common abnormalities are drug-related or are due to underlying rheumatoid disease [<a href="#rid27">27,28</a>]. Furthermore, data are conflicting about the development and progression of chronic fibrotic lung disease during treatment with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, and more recent studies have failed to document an association [<a href="#rid25">25,29,30</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review and meta-analysis (22 studies with 8584 participants) reported a small increase in respiratory adverse events with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> treatment (RR 1.10, 95% CI 1.02-1.19), but the definition of ILD was not consistent across studies [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, support for the long-term safety of MTX comes from a multicenter, multiethnic case control study with 410 patients with RA and chronic fibrotic ILD and 673 patients with RA and no lung disease [<a href="#rid29">29</a>]. The study had discovery and replication steps, and the combined results showed that MTX use was not associated with an increased risk of ILD (odds ratio 0.43, 95% CI 0.26-0.69); ILD was detected later in RA patients taking MTX, than in those without MTX treatment. </p><p></p><p>As noted above, the differential diagnosis of MTX-induced lung disease includes infectious complications, which must be excluded prior to the initiation of immunosuppressive therapy to treat a possible drug reaction. Infections reported in the setting of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> therapy include <em>Pneumocystis jirovecii</em> pneumonia, cryptococcal pneumonia, invasive pulmonary aspergillosis, disseminated histoplasmosis, pulmonary <em>Nocardia</em> infection, and viral pneumonia (eg, parainfluenza and cytomegalovirus) [<a href="#rid6">6,8-13</a>]. (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p class="headingAnchor" id="H11"><span class="h2">Leflunomide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">Leflunomide</a> is a DMARD used in RA that blocks a key enzyme of pyrimidine synthesis in activated lymphocytes. ILD and cases of new or accelerated pulmonary nodule formation have been reported, although the exact pathogenesis is not known [<a href="#rid3">3,31-35</a>]. As with other immunosuppressive agents, leflunomide is associated with an increased risk of infection in some [<a href="#rid36">36</a>], but not all studies [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/7515.html" rel="external">"Pharmacology, dosing, and adverse effects of leflunomide in the treatment of rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H360854319"><span class="h3">Interstitial pneumonitis</span><span class="headingEndMark"> — </span>Data on the risk of interstitial pneumonitis due to <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> are conflicting [<a href="#rid3">3,33-38</a>]. Overall, the risk appears low, except possibly in patients with underlying ILD or a history of MTX-induced lung toxicity. We generally avoid leflunomide in such patients, realizing the limitations of the data. Decisions need to be individualized, however, as the benefits of leflunomide may be substantial. </p><p>Studies showing the range of findings with <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review and meta-analysis that included eight clinical trials with 4579 participants suggested a decreased risk of noninfectious respiratory adverse events (RR 0.64, 95% CI 0.41-0.97) with <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> compared with MTX or placebo [<a href="#rid37">37</a>]. This analysis supports the contention that "channelling bias" may explain the results of the above observational studies. However, clinical trials would have excluded patients with underlying ILD. Thus, the safety of leflunomide in these patients requires further study. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a review that used linked prescribing and administrative databases for more than 235,000 patients with RA, the relative risk of ILD among those treated with <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> was 1.9 compared to those treated with other DMARDs [<a href="#rid38">38</a>]. However, there was no significant increase in risk among patients who had no prior diagnosis of ILD and no prior MTX use. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar findings were reported in an observational study of 5054 patients who were treated with <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>; 1.2 percent developed new or worsening ILD [<a href="#rid39">39</a>]. Risk factors included preexisting lung disease (most important factor) with an odds ratio of 8.17 (95% CI 4.63-14.4), smoking, low body weight, and use of a loading dose. </p><p></p><p>Pneumonitis due to <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> usually presents within the first 20 weeks of therapy and may occur after cessation of the medication [<a href="#rid34">34,40-42</a>]. Typical symptoms are fever, cough, and dyspnea. The main findings on high resolution computed tomography (HRCT) are ground glass opacities, bilateral reticular opacities, and honeycombing, although areas of consolidation can also be seen [<a href="#rid34">34,43</a>]. Eosinophilia in the bronchoalveolar lavage (BAL) fluid has been described [<a href="#rid42">42</a>]. Lung biopsies show interstitial pneumonitis (sometimes with eosinophilia), organizing pneumonia, or diffuse alveolar damage.</p><p>In one report, leflunomide-induced pneumonitis was fatal for 11 of 29 patients [<a href="#rid32">32</a>]. In another report, there were no fatalities; the authors attributed this to prompt recognition and treatment with glucocorticoids and <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a> [<a href="#rid33">33</a>]. </p><p><a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">Leflunomide</a> has a long half-life. Because of the hepatobiliary circulation of leflunomide, <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a> resin (eg, 8 g/day for three days) can be used to hasten elimination [<a href="#rid32">32,44</a>]. (See  <a class="medical medical_review" href="/z/d/html/7515.html" rel="external">"Pharmacology, dosing, and adverse effects of leflunomide in the treatment of rheumatoid arthritis", section on 'Pregnancy and lactation'</a>.) </p><p class="headingAnchor" id="H360854331"><span class="h3">Rheumatoid pulmonary nodules</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">Leflunomide</a> is also associated with appearance or accelerated progression of rheumatoid (necrobiotic) pulmonary nodules, which can occasionally lead to pneumothorax [<a href="#rid31">31,45,46</a>]. Development of pulmonary rheumatoid nodules may be associated with cough and low grade fever [<a href="#rid31">31,46</a>]. On imaging studies, the nodules may be cavitary [<a href="#rid31">31</a>]. Cessation of leflunomide usually leads to improvement or resolution of the nodules. (See  <a class="medical medical_review" href="/z/d/html/7523.html" rel="external">"Rheumatoid nodules"</a> and  <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">"Overview of pleuropulmonary diseases associated with rheumatoid arthritis", section on 'Rheumatoid lung nodules'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Biological agents</span><span class="headingEndMark"> — </span>Despite broad use of biologic agents to treat RA, cases of substantial pulmonary toxicity are infrequently reported [<a href="#rid3">3,21,47,48</a>]. In general, the biologic agents, tumor necrosis factor (TNF)-alpha blockers (soluble p75 TNF receptor fusion protein [<a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>], dimeric anti-TNF-alpha antibody [<a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>], anti-TNF-alpha monoclonal antibody [<a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>]), interleukin (IL)-1 blockers (<a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>), anti-B-cell monoclonal antibody (<a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>), and a selective costimulation modulator which prevents T cell CD28 binding (<a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>), have been shown to improve symptoms and joint disease, and possibly also lung disease in patients with RA [<a href="#rid49">49-51</a>]. Case series have also reported patients with other pulmonary disorders, such as nodules and infection, in association with biologic therapies for RA. (See  <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases"</a>.)</p><p>Due to the infrequent occurrence of clinically significant ILD, the likelihood that these agents are used in patients with more severe RA, and the risk of reporting bias, it is difficult to ascertain the exact risk of drug-induced ILD or worsening of preexisting ILD [<a href="#rid3">3</a>]. The British Society for Rheumatology Biologics Register (BSRBR) prospectively collects data on all patients in the UK receiving biologic agents (&gt;8000 patients) [<a href="#rid52">52</a>]. An early report in the organization's newsletter suggested that the odds ratio for mortality was 4.4 times higher (95% CI 1.8-10.7) for those RA patients with preexisting pulmonary disease who were treated with biologics compared to those without pulmonary disease. However, further analysis of the BSRBR included a prospective study of 367 patients with preexisting ILD (299 on anti-TNF; 68 on DMARDS) [<a href="#rid53">53</a>]. The adjusted (overall) mortality rate ratio comparing anti-TNF-alpha agents with DMARDS was 0.81 (95% CI 0.38-1.73), suggesting that biologics do not increase overall mortality. On the other hand, ILD appeared to be a more common cause of death with biologic agents compared with DMARDs (age and sex adjusted mortality rate ratio 2.63, 95% CI 0.60-11.45), although the numbers were small. A systematic review of published reports of drug-induced ILD in RA estimated the overall the risk with biologic agents at around 1 percent, but the mortality associated with ILD due to anti-TNFa-agents was high at 35 percent, compared with estimates of 18 and 13 percent for <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> and MTX, respectively [<a href="#rid3">3</a>].</p><p>The British Society of Rheumatology performed a systematic review of non-TNF-alpha agents and, based on the limited available data, concluded that <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a> and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> appear less likely to exacerbate ILD than other biologic agents and may be preferred over anti-TNF agents in patients with RA requiring therapy with a biologic agent [<a href="#rid3">3,26,48</a>]. The importance of these findings is in balancing the great overall benefit of biologic agents in controlling RA with the relative rarity, but potential severity, of drug-induced ILD. Additionally, as new agents are introduced, clinicians should maintain a heightened awareness of the potential for any drug to cause lung complications.  </p><p class="headingAnchor" id="H360854816"><span class="h3">Inflammatory pneumonitis</span><span class="headingEndMark"> — </span>Drug-induced ILD has been reported with the TNF-alpha inhibitors, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, and <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>, but not <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a> [<a href="#rid2">2,54,55</a>]. Development of new or worsening cough, dyspnea, and radiographic abnormalities should alert the clinician to the possibility of drug-induced ILD. </p><p>The frequency of drug-induced ILD and the possibility that underlying ILD can potentiate this process are illustrated by the following studies, and are summarized in a review [<a href="#rid21">21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">Etanercept</a><strong> and </strong><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a><strong> (TNF-alpha inhibitors)</strong> – Drug-induced ILD is uncommon, but potentially severe in patients treated with etanercept or infliximab, particularly patients aged 65 or older and those with preexisting ILD [<a href="#rid20">20,48</a>]. Among 108 patients with RA who developed new-onset or worsening of preexisting ILD while taking these agents, the majority of cases developed after the first six months of therapy. Drug-discontinuation and glucocorticoids resulted in improvement or resolution in approximately 65 percent, but progressive and death in 12 percent. In an observational study of 7091 patients with RA who were treated with etanercept, ILD developed in 42 (0.6 percent) [<a href="#rid56">56</a>]. A number of case reports have described lung toxicity as well. A patient with a prior history of MTX therapy developed lung injury eight weeks after initiation of etanercept, but responded to cessation of etanercept and treatment with oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 mg/day [<a href="#rid57">57</a>]. In two small case series, 10 patients with RA developed progressive usual interstitial pneumonitis (UIP) temporally related to initiation of infliximab or etanercept, and one developed organizing pneumonia; eight patients died from progressive UIP [<a href="#rid58">58,59</a>]. Among the fatal cases, all had preexisting ILD with a UIP pattern and three were concomitantly taking <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> and glucocorticoids. In these patients, MTX had been avoided because of the preexisting lung disease. Three cases of acute interstitial pneumonitis have been reported shortly after addition of infliximab in patients taking a stable dose of MTX [<a href="#rid60">60</a>]. All patients improved with discontinuation of MTX and infliximab and treatment with <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">Adalimumab</a><strong> (TNF-alpha inhibitor) </strong>– One patient with RA on a stable dose of MTX developed rapidly worsening ILD after initiation of adalimumab [<a href="#rid61">61</a>]. Respiratory improvement followed discontinuation of MTX and adalimumab, and treatment with oral <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Certolizumab (TNF-alpha inhibitor) </strong>– In a patient with refractory RA despite MTX and <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>, certolizumab was added with subsequent development of dry cough, breathlessness, and basilar crackles [<a href="#rid62">62</a>]. Ground glass and reticular opacities were noted on computed tomography (CT). Despite cessation of certolizumab and administration of systemic glucocorticoids, the patient experienced progressive respiratory failure. Among 4049 patients with RA treated with certolizumab, no instances of drug-induced ILD were reported [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a><strong> (CD-20 antibody) </strong>– Several case reports have described ILD associated with rituximab therapy for hematologic malignancies, but only a few have described ILD in patients with RA [<a href="#rid64">64-67</a>]. In a report of patients with underlying RA-associated ILD who were treated with rituximab, one experienced further progression and another developed acute respiratory distress syndrome due to possible pneumonia [<a href="#rid66">66</a>]. A separate report described development of organizing pneumonia in a patient with RA treated with rituximab and MTX [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/z/d/html/4336.html" rel="external">"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Rituximab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">Tocilizumab</a><strong> (interleukin [IL]-6 receptor antibody) </strong>– Isolated cases of combined pulmonary fibrosis with emphysema, ILD, acute pneumonitis, and idiopathic pulmonary fibrosis have been reported with tocilizumab (monoclonal antibody to interleukin-6) [<a href="#rid68">68-72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">Anakinra</a><strong> (IL-1 inhibitor) </strong>– Although infrequently used in the treatment of RA, anakinra has been associated with ILD in a small number of patients [<a href="#rid73">73-75</a>].</p><p></p><p>Treatment of drug-induced ILD due to the various biologic agents requires cessation of the drug; concomitantly administered DMARDs (eg, MTX, <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>) will also need to be stopped. If it is unclear which agent caused the lung toxicity, cautious reintroduction of one of the agents may be possible after resolution of symptoms and radiographic changes. Alternatively, a different biologic agent or DMARD may need to be substituted. </p><p>The efficacy of systemic glucocorticoids in this setting is not known. For patients who have stable or improving pneumonitis after cessation of the drug, glucocorticoids are generally withheld and the patient observed, as resolution of pulmonary toxicity often accompanies drug discontinuation. In contrast, empiric glucocorticoid therapy is usually initiated in a patient who has rapidly progressive or more severe pulmonary toxicity, although scientific evidence to support this practice is lacking.</p><p>As noted, these reports describe the potential for serious, adverse effects with biologic agents, particularly among patients with preexisting RA-induced ILD [<a href="#rid20">20</a>]. Predictors of which patients with RA-ILD are at greatest risk of a severe lung reaction have not been determined, but caution is advised for older adults, a UIP pattern, or severe disease [<a href="#rid76">76</a>]. However, biologic agents carry the potential for significant improvement in overall RA disease activity, so the balance of all factors should be considered when deciding to administer or withhold TNF-alpha blockers in patients with preexisting RA-induced ILD. </p><p class="headingAnchor" id="H360854822"><span class="h3">Granulomatous lung disease</span><span class="headingEndMark"> — </span>Lung disease characterized by granuloma formation (both noncaseating and necrotizing) without evidence of mycobacterial or fungal infection has been reported in a number of case reports [<a href="#rid77">77-82</a>]. In the largest series, six patients were on <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, two <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, and three <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>; some were also taking <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> or MTX [<a href="#rid82">82</a>]. Symptoms of cough, dyspnea, chest pain, or asthenia were reported by five of the patients. Imaging revealed single, multiple, or cavitary nodules; one patient had hilar adenopathy. Anti-TNF-alpha therapy was discontinued in six patients, but maintained in the others. Two patients were treated with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> after discontinuation of anti-TNF-alpha therapy, with resolution of the nodules.</p><p class="headingAnchor" id="H13"><span class="h3">Infections</span><span class="headingEndMark"> — </span>A variety of serious infections have been described with use of biologic agents to treat RA, especially TNF-alpha inhibitors. The presence of underlying chronic obstructive pulmonary disease (COPD) and the combination of biologic agents with glucocorticoids or other immunomodulatory agents may further increase the risk of infection [<a href="#rid15">15</a>]. Presenting symptoms may be subtle, and a high degree of clinical suspicion for infection should be applied in the assessment of patients treated with these agents.</p><p>In one study of 5326 patients, a four-fold increase in hospitalization due to infection was attributed to use of TNF-alpha inhibitors, compared with a two-fold increase that was associated with MTX [<a href="#rid16">16</a>]. The most common infection was bacterial pneumonia. In a separate observational study of 7091 patients taking <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, pneumonia occurred in 0.8 percent [<a href="#rid56">56</a>]. In a retrospective study in 146 older adults receiving biological agents for rheumatoid arthritis, the most common severe adverse reaction was infection, which occurred in 32 patients (22 percent) [<a href="#rid83">83</a>]. A variety of opportunistic infections (eg, <em>Listeria</em>, <em>Mycobacteria tuberculosis</em>, <em>Coccidioides</em>, <em>Histoplasma</em> and other fungal species, and cytomegalovirus) are noted in case reports and series. (See  <a class="medical medical_review" href="/z/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"</a> and  <a class="medical medical_review" href="/z/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a>.) </p><p><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> has also been associated with serious infections, including bacterial pneumonia and Pneumocystis pneumonia [<a href="#rid15">15,84-86</a>]. It is not clear if the incidence of most of these infections is greater than that associated with other DMARDs [<a href="#rid87">87</a>]. </p><p>The incidence of serious infections is approximately doubled when <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a> is added to a TNF-alpha inhibitor [<a href="#rid50">50</a>].</p><p>The use of <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> at high dose may increase the risk of serious infection, although further data are needed [<a href="#rid86">86</a>].</p><p>The guidelines from the British Society for Rheumatology assessed the risk of infection with TNF and non-TNF biological agents and found a lower risk of infection with <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> or <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a> compared with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in patients at high risk of infection [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Tuberculosis screening</span><span class="headingEndMark"> — </span>TNF-alpha inhibitors are associated with an increased risk of reactivation tuberculosis (TB). Appropriate screening before the start of treatment and vigilance for the occurrence of active TB during therapy are essential, although screening does not eliminate the risk of development of active TB. These issues are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors", section on 'Screening'</a>.)</p><p class="headingAnchor" id="H391091563"><span class="h2">Sulfasalazine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a>, which is sometimes used in combination therapy regimens for RA, has been associated with pneumonitis, commonly in conjunction with fever and rash [<a href="#rid3">3,88</a>]. Nearly half of affected patients present with the clinical syndrome of pulmonary infiltrates with eosinophilia [<a href="#rid88">88</a>]. Drug reaction with eosinophilia and systemic symptoms (DRESS) is also reported [<a href="#rid89">89,90</a>]. Cough and crackles on lung examination are commonly present. Eosinophil counts in the peripheral blood range from 432 to 7500/mm<sup>3</sup>. (See  <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p>Clinical improvement typically follows cessation of <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, while progressive respiratory failure and death occurred in two of three patients who continued the medication. The role of systemic glucocorticoid therapy is not well-studied, as most patients improve with sulfasalazine withdrawal. Among 20 patients treated with systemic glucocorticoids, 13 had complete symptom resolution, 3 improved, 1 had persistent disease, and 3 died of progressive respiratory failure. Rechallenge is not recommended.</p><p>Other pulmonary disorders associated with <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> include nonspecific interstitial pneumonia, organizing pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia), granulomatous lung disease, bronchiolitis obliterans, and rarely pleural effusion [<a href="#rid88">88,91-93</a>].</p><p class="headingAnchor" id="H1607918548"><span class="h2">Nonsteroidal anti-inflammatory drugs</span><span class="headingEndMark"> — </span>Nonsteroidal anti-inflammatory drugs (NSAIDs) have both analgesic and antiinflammatory properties, but do not alter articular outcomes in RA. Several NSAIDs (eg, <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>, <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a>, <a class="drug drug_general" data-topicid="9357" href="/z/d/drug information/9357.html" rel="external">diflunisal</a>) have been associated with pulmonary infiltrates with eosinophilia, but not all of these reports were in patients with RA [<a href="#rid94">94-98</a>]. It is not known whether this is a class effect or a unique feature of certain NSAIDs. </p><p>Cessation of the implicated agent is indicated, as resolution of pulmonary toxicity often accompanies drug discontinuation. Systemic glucocorticoids are generally withheld as long as pneumonitis is stable or improving. In contrast, empiric glucocorticoid therapy is usually initiated in a patient who has rapidly progressive or more severe pulmonary toxicity, although data to support this practice are limited to case reports. (See  <a class="medical medical_review" href="/z/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects", section on 'Pulmonary infiltrates with eosinophilia'</a>.)</p><p class="headingAnchor" id="H1736037282"><span class="h2">Rarely used medications</span></p><p class="headingAnchor" id="H16"><span class="h3">Gold</span><span class="headingEndMark"> — </span>Pneumonitis due to gold therapy is well recognized but uncommon, particularly now that more effective treatments for RA have supplanted the use of gold. Several forms of pulmonary disease occur among patients treated with gold, including nonspecific interstitial pneumonitis, organizing pneumonia, and bronchiolitis obliterans [<a href="#rid99">99</a>]. Of these, nonspecific interstitial pneumonitis is the most common.</p><p>Features of gold-induced pneumonitis that may allow differentiation from underlying RA-induced ILD include the presence of fever (50 percent), absence of clubbing (1 percent), BAL lymphocytosis (70 percent) rather than neutrophilia, and extrapulmonary signs of gold toxicity, such as a skin rash (36 percent), eosinophilia (36 percent), liver dysfunction (19 percent), and proteinuria (19 percent) [<a href="#rid99">99</a>]. Gold-induced pneumonitis typically begins within the first six months of therapy.</p><p>Gold therapy should be permanently discontinued in all cases. Although data are very limited, systemic glucocorticoid therapy (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 to 60 mg per day, followed by a two to six month taper) is usually initiated (after exclusion of infectious etiologies) when respiratory impairment is severe or when drug discontinuation does not lead to improvement [<a href="#rid100">100</a>]. Clinical remission (ie, improved symptoms and normalization of the chest radiograph or pulmonary function tests) occurs in most patients.</p><p class="headingAnchor" id="H17"><span class="h3">Penicillamine</span><span class="headingEndMark"> — </span>Pulmonary complications related to <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a> are rare, particularly given that more effective treatments for RA are preferred [<a href="#rid1">1,101</a>]. Original reports of bronchiolitis obliterans in patients with RA suggested that penicillamine was the causative agent, but bronchiolitis obliterans also occurs in the absence of penicillamine in patients with RA, and this association has not been seen in other patients using penicillamine (eg, in Wilson disease).</p><p>Bronchiolitis obliterans in patients with RA on <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a> has been described between 3 and 14 months after the initiation of therapy [<a href="#rid1">1,102</a>]. Patients present with typical clinical, radiographic, and pathologic features of bronchiolitis obliterans, including dyspnea, hyperinflation, airway obstruction, and air trapping. Additional features and treatment of bronchiolitis obliterans are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4323.html" rel="external">"Overview of bronchiolar disorders in adults", section on 'Bronchiolitis obliterans'</a>.)</p><p>Other rare complications of <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a> include membranous nephropathy, drug-induced lupus erythematosus, pulmonary hemorrhage, and interstitial fibrosis [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">"Drug-induced lupus"</a> and  <a class="medical medical_review" href="/z/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Drugs'</a>.)</p><p class="headingAnchor" id="H1541248226"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116127.html" rel="external">"Society guideline links: Rheumatoid arthritis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/118793.html" rel="external">"Society guideline links: Interstitial lung disease"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Most of the drugs used to treat rheumatoid arthritis (RA) have been reported to cause pneumonitis, including <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>, biologic agents, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, gold, <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a>, and nonsteroidal antiinflammatory drugs (NSAIDs). Many of the pulmonary reactions to drugs used for the treatment of rheumatoid arthritis are rare and are published as case reports, but have a high mortality. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary disease may infrequently occur with the relatively low doses of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (&lt;20 mg per week) that are used in patients with RA. There is no clear evidence that methotrexate contributes to chronic progressive fibrosing pneumonitis. (See <a class="local">'Methotrexate'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with methotrexate-induced pneumonitis, the chest radiograph typically demonstrates diffuse bilateral reticular opacities or mixed reticular and ground glass patterns (40 percent). Unilateral or nodular changes, effusions, and bilateral hilar lymphadenopathy are uncommon. Early drug discontinuation at the onset of respiratory symptoms may obviate the need for invasive testing. (See <a class="local">'Methotrexate'</a> above and  <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">"Methotrexate-induced lung injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interstitial pneumonitis and new and accelerated pulmonary rheumatoid nodule formation have been described with <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>, although the risk appears low. We generally avoid leflunomide in patients with underlying lung disease or a history of methotrexate-induced lung toxicity, but gathering evidence suggests this may not be necessary. (See <a class="local">'Leflunomide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New onset or progressive pneumonitis may uncommonly occur in patients treated with the tumor necrosis factor-alpha (TNF-alpha) blockers. A growing number of other biologic agents are being used to treat RA; further study is needed to determine whether they also cause or contribute to RA-associated interstitial pneumonitis. (See <a class="local">'Inflammatory pneumonitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TNF-alpha inhibitors are associated with an increased risk of reactivation tuberculosis (TB) and other opportunistic infections. Appropriate screening before the start of treatment and vigilance for the occurrence of active TB during therapy are essential. (See <a class="local">'Tuberculosis screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Granulomatous lung disease and hilar adenopathy are also associated with TNF-alpha inhibitors in the absence of demonstrable mycobacterial or fungal infection. Beyond careful exclusion of infection, the optimal management is not known. (See <a class="local">'Granulomatous lung disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The rarely used medications, gold and <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a>, have been associated with interstitial lung disease and bronchiolitis, respectively. (See <a class="local">'Rarely used medications'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Libby D, White DA. Pulmonary toxicity of drugs used to treat systemic autoimmune diseases. Clin Chest Med 1998; 19:809.</a></li><li class="breakAll">Camus P. The Drug-Induced Respiratory Disease Website. www.pneumotox.com (Accessed on April 21, 2016).</li><li><a class="nounderline abstract_t">Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 2014; 43:613.</a></li><li><a class="nounderline abstract_t">Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015; 386:258.</a></li><li><a class="nounderline abstract_t">Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther 2015; 17:362.</a></li><li><a class="nounderline abstract_t">Katsuyama T, Saito K, Kubo S, et al. Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. Arthritis Res Ther 2014; 16:R43.</a></li><li><a class="nounderline abstract_t">Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54:628.</a></li><li><a class="nounderline abstract_t">Belin V, Tebib J, Vignon E. Cytomegalovirus infection in a patient with rheumatoid arthritis. Joint Bone Spine 2003; 70:303.</a></li><li><a class="nounderline abstract_t">LeMense GP, Sahn SA. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 1994; 150:258.</a></li><li><a class="nounderline abstract_t">O'Reilly S, Hartley P, Jeffers M, et al. Invasive pulmonary aspergillosis associated with low dose methotrexate therapy for rheumatoid arthritis: a case report of treatment with itraconazole. Tuber Lung Dis 1994; 75:153.</a></li><li><a class="nounderline abstract_t">Stenger AA, Houtman PM, Bruyn GA, et al. Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis. Scand J Rheumatol 1994; 23:51.</a></li><li><a class="nounderline abstract_t">Cornelissen JJ, Bakker LJ, Van der Veen MJ, et al. Nocardia asteroides pneumonia complicating low dose methotrexate treatment of refractory rheumatoid arthritis. Ann Rheum Dis 1991; 50:642.</a></li><li><a class="nounderline abstract_t">Altz-Smith M, Kendall LG Jr, Stamm AM. Cryptococcosis associated with low-dose methotrexate for arthritis. Am J Med 1987; 83:179.</a></li><li><a class="nounderline abstract_t">van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, et al. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 2003; 29:2327.</a></li><li><a class="nounderline abstract_t">Khan S, Justice E, Jobanputra P. Adverse reactions and safety of newer disease-modifying antirheumatic drugs (DMARD) for rheumatoid arthritis. Adverse Drug React Bull 2007; 242:927.</a></li><li><a class="nounderline abstract_t">Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56:1125.</a></li><li><a class="nounderline abstract_t">Cannon GW. Antirheumatic drug reactions in the lung. Baillieres Clin Rheumatol 1993; 7:147.</a></li><li><a class="nounderline abstract_t">Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis 2003; 62 Suppl 2:ii2.</a></li><li><a class="nounderline abstract_t">Cannon GW. Methotrexate pulmonary toxicity. Rheum Dis Clin North Am 1997; 23:917.</a></li><li><a class="nounderline abstract_t">Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011; 41:256.</a></li><li><a class="nounderline abstract_t">Jani M, Hirani N, Matteson EL, Dixon WG. The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol 2014; 10:284.</a></li><li><a class="nounderline abstract_t">Scherak O, Popp W, Kolarz G, et al. Bronchoalveolar lavage and lung biopsy in rheumatoid arthritis. In vivo effects of disease modifying antirheumatic drugs. J Rheumatol 1993; 20:944.</a></li><li><a class="nounderline abstract_t">Flieder DB, Travis WD. Pathologic characteristics of drug-induced lung disease. Clin Chest Med 2004; 25:37.</a></li><li><a class="nounderline abstract_t">Barrera P, Laan RF, van Riel PL, et al. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994; 53:434.</a></li><li><a class="nounderline abstract_t">Conway R, Low C, Coughlan RJ, et al. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol 2014; 66:803.</a></li><li class="breakAll">Spanish Society of Rheumatology. Clinical practice guidelines for the management of paitients with rheumatoid arthritis. https://www.ser.es/wp-content/uploads/2020/04/Clinical-Practice-Guidelines-for-the-Management-of-Patients-with-Rheumatoid-Arthritis.pdf. (Accessed on October 19, 2021).</li><li><a class="nounderline abstract_t">Dawson JK, Graham DR, Desmond J, et al. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 2002; 41:262.</a></li><li><a class="nounderline abstract_t">Belzunegui J, Intxausti JJ, De Dios JR, et al. Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate. Clin Exp Rheumatol 2001; 19:727.</a></li><li><a class="nounderline abstract_t">Juge PA, Lee JS, Lau J, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J 2021; 57.</a></li><li><a class="nounderline abstract_t">Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 2007; 36:172.</a></li><li><a class="nounderline abstract_t">Rozin A, Yigla M, Guralnik L, et al. Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy. Clin Rheumatol 2006; 25:384.</a></li><li><a class="nounderline abstract_t">Ito S, Sumida T. Interstitial lung disease associated with leflunomide. Intern Med 2004; 43:1103.</a></li><li><a class="nounderline abstract_t">Ju JH, Kim SI, Lee JH, et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum 2007; 56:2094.</a></li><li><a class="nounderline abstract_t">Chikura B, Lane S, Dawson JK. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford) 2009; 48:1065.</a></li><li><a class="nounderline abstract_t">Raj R, Nugent K. Leflunomide-induced interstitial lung disease (a systematic review). Sarcoidosis Vasc Diffuse Lung Dis 2013; 30:167.</a></li><li><a class="nounderline abstract_t">Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009; 32:1123.</a></li><li><a class="nounderline abstract_t">Conway R, Low C, Coughlan RJ, et al. Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials. J Rheumatol 2016; 43:855.</a></li><li><a class="nounderline abstract_t">Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006; 54:1435.</a></li><li><a class="nounderline abstract_t">Sawada T, Inokuma S, Sato T, et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 2009; 48:1069.</a></li><li><a class="nounderline abstract_t">Takeishi M, Akiyama Y, Akiba H, et al. Leflunomide induced acute interstitial pneumonia. J Rheumatol 2005; 32:1160.</a></li><li><a class="nounderline abstract_t">Kamata Y, Nara H, Kamimura T, et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 2004; 43:1201.</a></li><li><a class="nounderline abstract_t">Hamilton JA, Bishop JM. 69-year-old woman with rheumatoid arthritis presents with shortness of breath and cough. Ann Am Thorac Soc 2014; 11:1653.</a></li><li><a class="nounderline abstract_t">Sakai F, Noma S, Kurihara Y, et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol 2005; 15:173.</a></li><li><a class="nounderline abstract_t">Wong SP, Chu CM, Kan CH, et al. Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy. J Clin Rheumatol 2009; 15:389.</a></li><li><a class="nounderline abstract_t">Kim SH, Yoo WH. Recurrent pneumothorax associated with pulmonary nodules after leflunomide therapy in rheumatoid arthritis: a case report and review of the literature. Rheumatol Int 2011; 31:919.</a></li><li><a class="nounderline abstract_t">Horvath IF, Szanto A, Csiki Z, et al. Intrapulmonary rheumatoid nodules in a patient with long-standing rheumatoid arthritis treated with leflunomide. Pathol Oncol Res 2008; 14:101.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, et al. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 2011; 124:386.</a></li><li><a class="nounderline abstract_t">Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology (Oxford) 2019; 58:e3.</a></li><li><a class="nounderline abstract_t">Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002; 122:1093.</a></li><li><a class="nounderline abstract_t">Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013; 72 Suppl 2:ii2.</a></li><li><a class="nounderline abstract_t">Morgan CL, Emery P, Porter D, et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology (Oxford) 2014; 53:186.</a></li><li><a class="nounderline abstract_t">Watson K, Symmons D, Griffiths I, Silman A. The British Society for Rheumatology biologics register. Ann Rheum Dis 2005; 64 Suppl 4:iv42.</a></li><li><a class="nounderline abstract_t">Dixon WG, Hyrich KL, Watson KD, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010; 69:1086.</a></li><li><a class="nounderline abstract_t">Weinblatt ME, Moreland LW, Westhovens R, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol 2013; 40:787.</a></li><li><a class="nounderline abstract_t">Harigai M, Ishiguro N, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2016; 26:491.</a></li><li><a class="nounderline abstract_t">Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009; 36:898.</a></li><li><a class="nounderline abstract_t">Hagiwara K, Sato T, Takagi-Kobayashi S, et al. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol 2007; 34:1151.</a></li><li><a class="nounderline abstract_t">Ostör AJ, Chilvers ER, Somerville MF, et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 2006; 33:622.</a></li><li><a class="nounderline abstract_t">Tengstrand B, Ernestam S, Engvall IL, et al. [TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports]. Lakartidningen 2005; 102:3788.</a></li><li><a class="nounderline abstract_t">Kramer N, Chuzhin Y, Kaufman LD, et al. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2002; 47:670.</a></li><li><a class="nounderline abstract_t">Huggett MT, Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford) 2006; 45:1312.</a></li><li><a class="nounderline abstract_t">Glaspole IN, Hoy RF, Ryan PF. A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2013; 52:2302.</a></li><li><a class="nounderline abstract_t">Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis 2015; 74:96.</a></li><li><a class="nounderline abstract_t">Soubrier M, Jeannin G, Kemeny JL, et al. Organizing pneumonia after rituximab therapy: Two cases. Joint Bone Spine 2008; 75:362.</a></li><li><a class="nounderline abstract_t">Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007; 46:626.</a></li><li><a class="nounderline abstract_t">Matteson EL, Bongartz T, Ryu JH, et al. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheumatol Autoimmun Dis 2012; 2:53.</a></li><li><a class="nounderline abstract_t">Naqibullah M, Shaker SB, Bach KS, Bendstrup E. Rituximab-induced interstitial lung disease: five case reports. Eur Clin Respir J 2015; 2.</a></li><li><a class="nounderline abstract_t">Wendling D, Vidon C, Godfrin-Valnet M, et al. Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis. Joint Bone Spine 2013; 80:670.</a></li><li><a class="nounderline abstract_t">Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 2011; 70:2148.</a></li><li><a class="nounderline abstract_t">Sangüesa Gómez C, Flores Robles BJ, Jara Chinarro B, et al. Acute pneumonitis in a patient with adult-onset disease after toclizumab treatment with good response to anakinra. Reumatol Clin 2016; 12:345.</a></li><li><a class="nounderline abstract_t">Kawashiri SY, Kawakami A, Sakamoto N, et al. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int 2012; 32:4023.</a></li><li><a class="nounderline abstract_t">Akiyama M, Kaneko Y, Yamaoka K, et al. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. Rheumatol Int 2016; 36:881.</a></li><li><a class="nounderline abstract_t">Hadjinicolaou AV, Nisar MK, Bhagat S, et al. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review. Rheumatology (Oxford) 2011; 50:2297.</a></li><li><a class="nounderline abstract_t">Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004; 63:1062.</a></li><li><a class="nounderline abstract_t">Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65:1006.</a></li><li><a class="nounderline abstract_t">Mori S. Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis. Clin Med Insights Circ Respir Pulm Med 2015; 9:41.</a></li><li><a class="nounderline abstract_t">Peno-Green L, Lluberas G, Kingsley T, Brantley S. Lung injury linked to etanercept therapy. Chest 2002; 122:1858.</a></li><li><a class="nounderline abstract_t">Ognenovski VM, Ojo TC, Fox DA. Etanercept-associated pulmonary granulomatous inflammation in patients with rheumatoid arthritis. J Rheumatol 2008; 35:2279.</a></li><li><a class="nounderline abstract_t">Vavricka SR, Wettstein T, Speich R, et al. Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy. Thorax 2003; 58:278.</a></li><li><a class="nounderline abstract_t">Yousem SA, Dacic S. Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy. Mod Pathol 2005; 18:651.</a></li><li><a class="nounderline abstract_t">Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 2008; 26:471.</a></li><li><a class="nounderline abstract_t">Toussirot E, Berthelot JM, Pertuiset E, et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. J Rheumatol 2009; 36:2421.</a></li><li><a class="nounderline abstract_t">Leon L, Gomez A, Vadillo C, et al. Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 2018; 36:29.</a></li><li><a class="nounderline abstract_t">Teichmann LL, Woenckhaus M, Vogel C, et al. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:1256.</a></li><li><a class="nounderline abstract_t">Tai TL, O'Rourke KP, McWeeney M, et al. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford) 2002; 41:951.</a></li><li><a class="nounderline abstract_t">Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68:25.</a></li><li><a class="nounderline abstract_t">Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 2011; 31:1493.</a></li><li><a class="nounderline abstract_t">Parry SD, Barbatzas C, Peel ET, Barton JR. Sulphasalazine and lung toxicity. Eur Respir J 2002; 19:756.</a></li><li><a class="nounderline abstract_t">Gutierrez M, Filippucci E, Bugatti L, et al. [Severe drug hypersensitivity syndrome due to sulphasalazine in patient with rheumatoid arthritis]. Reumatismo 2009; 61:65.</a></li><li><a class="nounderline abstract_t">Michel F, Navellou JC, Ferraud D, et al. DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis. Joint Bone Spine 2005; 72:82.</a></li><li><a class="nounderline abstract_t">Ulubaş B, Sahin G, Ozer C, et al. Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis. Clin Rheumatol 2004; 23:249.</a></li><li><a class="nounderline abstract_t">Boyd O, Gibbs AR, Smith AP. Fibrosing alveolitis due to sulphasalazine in a patient with rheumatoid arthritis. Br J Rheumatol 1990; 29:222.</a></li><li><a class="nounderline abstract_t">Katsenos S, Antonogiannaki EM, Psathakis K. Sulfasalazine-induced Hypereosinophilic Obliterative Bronchiolitis. Arch Bronconeumol 2016; 52:108.</a></li><li><a class="nounderline abstract_t">Goodwin SD, Glenny RW. Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports. Arch Intern Med 1992; 152:1521.</a></li><li><a class="nounderline abstract_t">Pfitzenmeyer P, Meier M, Zuck P, et al. Piroxicam induced pulmonary infiltrates and eosinophilia. J Rheumatol 1994; 21:1573.</a></li><li class="breakAll">Foucher P, Camus P. Pneumotox online: the drug-induced lung diseases. www.pneumotox.com (Accessed on September 23, 2013).</li><li><a class="nounderline abstract_t">Karakatsani A, Chroneou A, Koulouris NG, et al. Meloxicam-induced pulmonary infiltrates with eosinophilia: a case report. Rheumatology (Oxford) 2003; 42:1112.</a></li><li><a class="nounderline abstract_t">Vogts N, Young S. Pulmonary infiltrates with eosinophilia syndrome in ibuprofen overdose. N Z Med J 2012; 125:74.</a></li><li><a class="nounderline abstract_t">Tomioka R, King TE Jr. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am J Respir Crit Care Med 1997; 155:1011.</a></li><li><a class="nounderline abstract_t">Blancas R, Moreno JL, Martín F, et al. Alveolar-interstitial pneumopathy after gold-salts compounds administration, requiring mechanical ventilation. Intensive Care Med 1998; 24:1110.</a></li><li><a class="nounderline abstract_t">Stein HB, Patterson AC, Offer RC, et al. Adverse effects of D-penicillamine in rheumatoid arthritis. Ann Intern Med 1980; 92:24.</a></li><li><a class="nounderline abstract_t">van de Laar MA, Westermann CJ, Wagenaar SS, Dinant HJ. Beneficial effect of intravenous cyclophosphamide and oral prednisone on D-penicillamine-associated bronchiolitis obliterans. Arthritis Rheum 1985; 28:93.</a></li></ol></div><div id="topicVersionRevision">Topic 4378 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9917966" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pulmonary toxicity of drugs used to treat systemic autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9917966" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pulmonary toxicity of drugs used to treat systemic autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24231065" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25975452" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26669566" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24495443" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16447241" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12951317" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cytomegalovirus infection in a patient with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8025760" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Opportunistic infection during treatment with low dose methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8032050" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Invasive pulmonary aspergillosis associated with low dose methotrexate therapy for rheumatoid arthritis: a case report of treatment with itraconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8108669" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1929588" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nocardia asteroides pneumonia complicating low dose methotrexate treatment of refractory rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605168" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cryptococcosis associated with low-dose methotrexate for arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14600805" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Adverse reactions and safety of newer disease-modifying antirheumatic drugs (DMARD) for rheumatoid arthritis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17393394" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8519072" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Antirheumatic drug reactions in the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14532138" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9361161" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Methotrexate pulmonary toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21277618" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24366321" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The safety of biologic therapies in RA-associated interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8102405" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bronchoalveolar lavage and lung biopsy in rheumatoid arthritis. In vivo effects of disease modifying antirheumatic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15062595" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pathologic characteristics of drug-induced lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7944614" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Methotrexate-related pulmonary complications in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24757133" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24757133" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11934961" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11791648" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32646919" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Methotrexate and rheumatoid arthritis associated interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17657669" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Rheumatoid arthritis treatment and the risk of severe interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16211338" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15645640" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Interstitial lung disease associated with leflunomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17530652" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19321511" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical expression of leflunomide-induced pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24284289" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Leflunomide-induced interstitial lung disease (a systematic review).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19916579" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980577" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16645972" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19321513" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15940779" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Leflunomide induced acute interstitial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15645660" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25549032" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : 69-year-old woman with rheumatoid arthritis presents with shortness of breath and cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17029058" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19955995" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19862529" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Recurrent pneumothorax associated with pulmonary nodules after leflunomide therapy in rheumatoid arthritis: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18392955" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Intrapulmonary rheumatoid nodules in a patient with long-standing rheumatoid arthritis treated with leflunomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21531225" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30137552" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12226061" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23532441" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24140761" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16239385" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The British Society for Rheumatology biologics register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20444754" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23588946" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26635183" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332630" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Postmarketing surveillance of the safety and effectiveness of etanercept in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17444583" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16511933" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16408702" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : [TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12522843" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16935921" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Adalimumab-associated pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23661426" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092417" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18424211" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Organizing pneumonia after rituximab therapy: Two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17189244" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26557260" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Rituximab-induced interstitial lung disease: five case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23618802" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21852254" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26602361" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Acute pneumonitis in a patient with adult-onset disease after toclizumab treatment with good response to anakinra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20480164" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27072347" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22019799" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15082469" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16396977" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Safety of extended treatment with anakinra in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26401101" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12426295" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Lung injury linked to etanercept therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19004058" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Etanercept-associated pulmonary granulomatous inflammation in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612312" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15529178" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18578973" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797509" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28598787" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18567919" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12154220" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Pneumocystis carinii pneumonia following a second infusion of infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18203761" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20473756" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11999006" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Sulphasalazine and lung toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19370190" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : [Severe drug hypersensitivity syndrome due to sulphasalazine in patient with rheumatoid arthritis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15681256" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15168156" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1972634" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Fibrosing alveolitis due to sulphasalazine in a patient with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25912939" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Sulfasalazine-induced Hypereosinophilic Obliterative Bronchiolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1627033" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7983669" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Piroxicam induced pulmonary infiltrates and eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7983669" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Piroxicam induced pulmonary infiltrates and eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12923267" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Meloxicam-induced pulmonary infiltrates with eosinophilia: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22932657" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Pulmonary infiltrates with eosinophilia syndrome in ibuprofen overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9116980" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9840249" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Alveolar-interstitial pneumopathy after gold-salts compounds administration, requiring mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7350870" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Adverse effects of D-penicillamine in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3966941" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Beneficial effect of intravenous cyclophosphamide and oral prednisone on D-penicillamine-associated bronchiolitis obliterans.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
